# Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)

> **NCT00704405** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 285 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Vaniprevir
- **DRUG:** Pegylated Interferon (Peg-IFN)
- **DRUG:** Ribavirin (RBV)
- **DRUG:** Placebo (PBO)

## Key facts

- **NCT ID:** NCT00704405
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03-27
- **Primary completion:** 2012-03-26
- **Final completion:** 2012-09-10
- **Target enrollment:** 285 (ACTUAL)
- **Last updated:** 2018-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00704405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00704405, "Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00704405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*